Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Drug marketing costs double R&D
Every self-respecting pharma exec will tell you: R&D is the industry's peculiar burden, the chief reason why brand-name drugs are so expensive. But the average Joe or Jane consumer thinks that's, er, a lot of bunk. It's marketing that drives the costs of their meds ever upward.
Now, a couple of academics have the figures. After combing through market research, they found that pharma spent $57.5 billion on marketing in 2004--almost twice the $31.5 billion spent on research that year, according to the National Science Foundation. And the research numbers include public funding, not just company expenses.
The data "confirms the public image of a marketing-driven industry," the study authors wrote. It also shows that the industry needs to be redirected toward research and away from brand-building, they wrote. Just how might that redirection happen? They didn't say.
- see this release release
-get the journal article from PLoS Medicine
Related Articles:
Study: DTC ad spending on the rise. Report
10 reforms for drug advertising. Report
FDA to study TV drug ad imagery. Report
Comments
R&D happens YEARS before the go to market launch and marketing of a product.
To get an accurate number on this, you would have to compare the R&D for a drug to the marketing expenditure on the drug on a case by case basis.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


